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INTRODUCTION
The luteinizing hormone-releasing hormone
(LH-RH) analogue induces a transient release of
luteinizing hormone (LH) with a consecutive in-
crease in testosterone, and this increase results in
exacerbation of clinical signs and symptoms in some
prostate cancer patients [1, 2]. Several studies have
demonstrated that this disease flare can be effec-
tively eliminated by the use of antiandrogens in
combination with or before initiation of LH-RH
analogue therapy [3-6]. However, the optimal
duration of pretreatment is rather difficult to deter-
mine. We herein report the endocrinological effects
of pretreatment with the steroidal antiandrogen,
chlormadinone acetate (CMA ; 6-chloro-3,20-dioxo-4,
6-pregnadien-17-yl acetate, Teikoku Hormone MFG
Co. Tokyo, Japan) for the prevention of this initial
testosterone surge.
PATIENTS AND METHODS
A total of 25 patients with previously untreated
prostate cancer (stage B, C, D) proved by biopsy were
included in this study. All patients gave informed
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consent to participate in the study. The patients were
assigned randomly to 2 treatment groups. Group 1
patients were treated with the depot LH-RH ana-
logue (leuprorelin acetate 3.75 mg or goserelin 3.6
mg) plus CMA. CMA therapy was begun 4 weeks
before the initial LH-RH analogue injection at a
dosage of 100 mg/day orally. Group 2 patients were
treated with the LH-RH analogue plus CMA at the
same dosages used in group 1 with the exception
that CMA therapy was begun 2 weeks before the
initial LH-RH analogue injection. After the initial
LH-RH analogue injection, CMA was administered
to both groups.
Serum LH, testosterone, and prostate specific
antigen (PSA) were measured in each patient before
the initial CMA administration, and on days 0, 3, 7,
and 28 of LH-RH analogue therapy. Serum LH
(Spack-S LH kit, Daiichi Radioisotope Laboratories
Ltd., Tokyo, Japan) and testosterone (Total Testos-
terone, Diagnostic Products Corporation, Los Angels,
USA) levels were measured by radioimmunoassay.
PSA assay was performed by themonoclonal Hybritech
Tandem-R immuno-radiometric technique (Tandem-R
PSA, Hybritech. Inc., San Diego, USA). Due to the
wide variation of the initial values of serum PSA, we
investigated the mean relative PSA levels. Relative
values were expressed as a percentage of the initial
value for each patient before therapy started, which
was considered 100%.
Histologically, differentiation of adenocarcinoma
was evaluated according to the criteria of the General
Rules for Clinical and Pathological Studies on
Prostatic Cancer [7]. Data are presented as means
±SD (standard deviation). For statistical analysis,
the Wilcoxon one sample analysis, paired Wilcoxon
test and Mann-Whitney U test were used and a P
value below 0.05 was considered to indicate statistical
significance.
RESULTS
The characteristics of the patients are shown in
table 1. There were no significant differences be-
tween the 2 treatment groups in the initial age,
histopathological grade, clinical stage, serum LH,
testosterone and PSA levels at the start of treat-
ment.
The mean absolute values of serum LH and tes-
tosterone in both groups are shown in figures 1
and 2. Pretreatment with CMA decreased serum
LH levels. Compared to day 0 (the initial injection
Fig.1. Effects of CMA pretreatment on serum LH in prostate
cancer patients. LH-RH analogue was administered on day 0.
Values are mean±S.D. ; Closed circle, Group 1, n=12 ; Open
circle, Group 2, n=13. *p<0.05, **p<0.01, ***p<0.001 vs. day 0.
Fig. 2. Effects of CMA pretreatment on serum testosterone in
prostate cancer patients. LH-RH analogue was administered on
day 0. Values are mean±S.D. ; Closed circle, Group 1, n=12 ;
Open circle, Group 2, n=13. **p<0.01, ***p<0.001 vs. day 0.
Table 1. Patient characteristics
Group 1
(n=12)
Group 2
(n=13)
Age (years) 75.5±8.0 75.4±7.0
Histopathological grade
Well
Moderate
Poor
4
5
3
2
4
7
Stage
B 1
B 2
C
D 2
2
2
4
4
3
3
6
1
LH (mIU/ml) 5.9±2.6 12.7±9.5
Testosterone (ng/dl) 422.2±152.7 528.2±173.7
PSA (ng/ml) 129.0±176.8 60.0±63.7
Values are means±S.D.
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of the LH-RH analogue), the serum LH levels were
increased on day 3 (Group 1 ; 2.83±2.22 vs. 4.06
±2.05mIU/ml, Group 2 ; 4.92±3.61 vs.7.95±5.23
mIU/ml), and then decreased. However, the serum
LH levels on day 3 did not reach pretreatment levels
in either group. There were no significant differ-
ences in serum LH levels between the groups on
days 0, 3, 7, and 28. The serum testosterone levels
showed a parallel decrease with LH until day 0,
and reached castration levels below 100 ng/dl in
both groups. Temporary increases were observed
on day 3 (Group 1 ; 138.12±95.82 ng/dl, Group 2 ;
202.58±81.70 ng/dl), but did not reach pretreat-
ment levels. On day 7, serum testosterone levels
decreased to castration levels in both groups. There
were no significant differences in serum testosterone
levels between the groups on days 0, 3, 7, and 28.
The mean relative values of serum PSA are shown
in figure 3. CMA pretreatment significantly reduced
serum PSA. On day 0, the mean relative values of
serum PSA in group 2 (45.31±24.76%) were higher
than those in group 1 (24.92±11.89%). There were
no significant differences among the groups on days
3, 7, and 28. In group 2, the mean relative values of
serum PSA were significantly lower on day 3 (38.26
±19.71%) and day 7 (35.25±19.62%) than on day 0
(45.31±24.76%). However, the mean relative PSA
levels were not lower on day 3 (25.26±12.34%) or
day 7 (27.68±12.31%) than on day 0 (24.92±11.89
%) in group 1. In 3 cases in group 1, the mean
relative values of serum PSA decreased in a linear
fashion after the initial injection of the LH-RH ana-
logue, and all 3 cases exhibited well differentiated
adenocarcinoma. In contrast, increases in the mean
relative values of serum PSA on day 7 compared to
days 0 or 3 were observed in 9 cases. The adeno-
carcinoma was well differentiated in 1 case, mod-
erate in 5, and poor in 3. Increases in the mean
relative values of serum PSA on day 7 were more
frequently seen in the patients with high histopatho-
logical grade (p<0.05). There was no correlation
between the change in mean relative values of
serum PSA and the clinical stage.
No signs or symptoms of disease flare were ob-
served in either group.
DISCUSSION
Since disease flare is considered to be due to the
initial increase in serum testosterone, the use of
antiandrogens in combination with or before ini-
tiation of a LH-RH analogue has been advocated.
Labrie et al. [3] reported that the concomitant
administration of the nonsteroidal antiandrogen,
flutamide, completely eliminated the risk of disease
flare. On the other hand, Schulze et al . [4] indicated
that pretreatment with flutamide for only 1 day may
not be sufficient to prevent tumor flare, and should
begin 1 week before the LH-RH analogue injection.
However, from an endocrinological viewpoint, the
effects of nonsteroidal antiandrogens in preventing
disease flare are rather difficult to determine due
to their mode of action [6]. Pretreatment with the
steroidal antiandrogen, cyproterone acetate, for 1
week prevented the LH-RH analogue induced tes-
tosterone surge and an initial increase in prostatic
acid phosphatase beyond the pretreatment levels
[4]. The administration of estramustine phosphate
560mg daily for 3 weeks prior to goserelin acetate
depot therapy was also considered sufficient to
prevent tumor flare [6].
The steroidal antiandrogen CMA was reported
to reduce serum testosterone levels and block the
binding of androgens to androgen receptors in
prostatic carcinoma tissue [8]. Nishimura et al . [9]
reported that the plasma testosterone concentration
decreased to levels of normal females after 4-6
weeks of CMA administration, but increased to an
average level of 109ng/dl after 8 -10 weeks of CMA
administration. Yoshida et al . [5] investigated the
efficacy of 2-week and 4-week pretreatment with 100
mg/day CMA to prevent disease flare in patients
with metastatic carcinoma of the prostate. Since
serum PSA levels significantly increased in the
2-week pretreatment group but showed a linear
Fig. 3. Effects of CMA pretreatment on mean relative values
of serum PSA in prostate cancer patients. LH-RH analogue was
administered on day 0. Values are mean±S.D. ; Closed circle,
Group 1, n=12 ; Open circle, Group 2, n=13. **p<0.01, ***p<0.001
vs. day 0.
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decrease in the 4-week pretreatment group, they
concluded that the 4-week regimen was more effec-
tive than the 2-week regimen [5]. However, there
are two major differences from our study. First,
CMA was discontinued after the LH-RH analogue
therapy in their study. Second, they investigated the
efficacy in patients with metastatic carcinoma of the
prostate.
In recent meta-analyses, maximal androgen
blockade (MAB) continues to be debated, with ad-
vocates both for and against its efficacy [10, 11]. In
the present study, CMA was continued after the
LH-RH analogue therapy for the purpose of MAB.
The serum LH and testosterone levels were in-
creased on day 3 compared to day 0, but did not
reach pretreatment levels in either group. The mean
relative values of serum PSA were significantly
lower on day 3 and day 7 than on day 0 in group 2.
However, the mean relative PSA levels were not
lower on days 3 or 7 than on day 0 in group 1, de-
spite the longer pretreatment. These results suggest
that pretreatment for 2 weeks is sufficient to pre-
vent the initial testosterone surge in the MAB which
is associated with CMA. PSA change induced by a
transient testosterone increase may be different in
each case, and it seems to be difficult to identify the
correlation factor. However, as shown in our results
the histopathological grade may contribute to the
difference. A larger prospective trial is necessary
to elucidate this factor.
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